科研之友
微信
新浪微博
Facebook
分享链接
摘要
Background and objectiveFractional exhaled nitric oxide (FeNO) has been used as a marker for airway inflammation. We evaluated the association between FeNO levels and asthma exacerbations (AEs) in Thai children and young adults. MethodsThis was a prospective cohort study in patients with atopic asthma aged 7-20years. Asthma control level and management were evaluated every 3months for 1year. Spirometry and FeNO measurements were performed at baseline, and 6 and 12months. ResultsIn all, 70 patients (median age: 12.6 (7.2-19.8) years) were enrolled, of whom 18% had an AE during the study period. Median FeNO levels were significantly higher in patients with an AE than in those without an AE (35.6ppb vs 16.5ppb; P=0.012). FeNO of 31ppb provided optimal sensitivity (92.3%) and specificity (75.4%) for AE prediction. Sensitivity and specificity of FeNO levels were higher than those of forced expiratory volume in 1s and forced expiratory flow at 25-75% of forced vital capacity bronchodilator reversibility for the prediction of an AE, but the difference was not significant (P=0.121). None of the patients with FeNO level of 0-20ppb had an AE within 12months. Percentage of patients with FeNO of 21-40ppb who suffered an AE was 20% and 30% at 6 and 12months, respectively. ConclusionThe optimal cut-off point of FeNO level for the prediction of AE is 31ppb. AE within the next 12months was significantly more common in patients with higher FeNO levels and in patients with a higher rate of previous 12-month exacerbations. The fractional exhaled nitric oxide (FeNO) level at a visit before an asthma exacerbation (AE) was significantly higher in asthmatic patients who experienced an AE within the next 12months. The optimal cut-off point of FeNO level for the prediction of an AE is 31ppb.
- 出版日期2017-1
